Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome.

Chamdin A, Jarzembowski JA, Subramanian C, Kuick R, Lee JS, Kwok RP, Castle VP, Opipari AW.

Transl Oncol. 2009 Aug 18;2(3):128-37.

2.

Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.

Coco S, Defferrari R, Scaruffi P, Cavazzana A, Di Cristofano C, Longo L, Mazzocco K, Perri P, Gambini C, Moretti S, Bonassi S, Tonini GP.

J Pathol. 2005 Nov;207(3):346-57.

PMID:
16178058
3.

Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory.

Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C, Cavazzana A, Stigliani S, Bonassi S, Tonini GP.

Cancer. 2008 Sep 15;113(6):1412-22. doi: 10.1002/cncr.23720.

4.

MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity.

Samaraweera L, Grandinetti KB, Huang R, Spengler BA, Ross RA.

BMC Cancer. 2014 May 2;14:309. doi: 10.1186/1471-2407-14-309.

5.

Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell.

Mora J, Cheung NK, Juan G, Illei P, Cheung I, Akram M, Chi S, Ladanyi M, Cordon-Cardo C, Gerald WL.

Cancer Res. 2001 Sep 15;61(18):6892-8.

6.

Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors.

Del Grosso F, Coco S, Scaruffi P, Stigliani S, Valdora F, Benelli R, Salvi S, Boccardo S, Truini M, Croce M, Ferrini S, Longo L, Tonini GP.

Mol Cancer Res. 2011 Jul;9(7):815-23. doi: 10.1158/1541-7786.MCR-10-0367. Epub 2011 Jun 3.

7.

Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.

Garcia I, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galván P, de Torres C, Mora J, Lavarino C.

Mol Cancer. 2010 Oct 15;9:277. doi: 10.1186/1476-4598-9-277.

8.

Kidins220/ARMS depletion is associated with the neural-to Schwann-like transition in a human neuroblastoma cell line model.

Rogers DA, Schor NF.

Exp Cell Res. 2013 Mar 10;319(5):660-9. doi: 10.1016/j.yexcr.2012.12.027. Epub 2013 Jan 16.

PMID:
23333500
9.

Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.

Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H.

BMC Cancer. 2010 May 5;10:181. doi: 10.1186/1471-2407-10-181.

10.

Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors.

Martin DT, Gendron RL, Jarzembowski JA, Perry A, Collins MH, Pushpanathan C, Miskiewicz E, Castle VP, Paradis H.

Clin Cancer Res. 2007 Mar 1;13(5):1480-7.

11.

Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.

Li D, Mei H, Pu J, Xiang X, Zhao X, Qu H, Huang K, Zheng L, Tong Q.

Mol Cancer. 2015 Feb 21;14:47. doi: 10.1186/s12943-015-0320-6.

12.

TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.

Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.

Cancer. 2004 Oct 15;101(8):1873-81.

13.

Laser-capture microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations.

Mora J, Akram M, Cheung NK, Chen L, Gerald WL.

Med Pediatr Oncol. 2000 Dec;35(6):534-7.

PMID:
11107110
14.

The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.

Schulte JH, Pentek F, Hartmann W, Schramm A, Friedrichs N, Øra I, Koster J, Versteeg R, Kirfel J, Buettner R, Eggert A.

Int J Cancer. 2009 May 15;124(10):2488-94. doi: 10.1002/ijc.24204.

15.

The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines.

Servidei T, Morosetti R, Ferlini C, Cusano G, Scambia G, Mastrangelo R, Koeffler HP.

Oncol Res. 2004;14(7-8):345-54.

PMID:
15301425
16.

Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells.

Acosta S, Lavarino C, Paris R, Garcia I, de Torres C, Rodríguez E, Beleta H, Mora J.

BMC Dev Biol. 2009 Feb 12;9:12. doi: 10.1186/1471-213X-9-12.

17.

The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.

Maitra A, Yashima K, Rathi A, Timmons CF, Rogers BB, Shay JW, Gazdar AF.

Cancer. 1999 Feb 1;85(3):741-9.

PMID:
10091748
18.

The clinical management and outcomes of cervical neuroblastic tumors.

Jackson JR, Tran HC, Stein JE, Shimada H, Patel AM, Marachelian A, Kim ES.

J Surg Res. 2016 Jul;204(1):109-13. doi: 10.1016/j.jss.2016.04.030. Epub 2016 Apr 23.

PMID:
27451875
19.

NUB-7: a stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages.

Dimitroulakos J, Squire J, Pawlin G, Yeger H.

Cell Growth Differ. 1994 Apr;5(4):373-84.

20.

Supplemental Content

Support Center